Medicenna Therapeutics (TSE:MDNA) Shares Up 14.3% – Time to Buy?

Medicenna Therapeutics Corp. (TSE:MDNA) shot up 14.3% during trading on Monday . The company traded as high as C$0.72 and last traded at C$0.72. 127,392 shares traded hands during trading, an increase of 20% from the average session volume of 105,837 shares. The stock had previously closed at C$0.63.

Medicenna Therapeutics Price Performance

The company has a market cap of C$55.06 million, a P/E ratio of -4.40 and a beta of 2.90. The company’s 50-day moving average price is C$0.69 and its two-hundred day moving average price is C$0.98. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30.

Medicenna Therapeutics (TSE:MDNA) last posted its quarterly earnings results on Thursday, April 30th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. As a group, sell-side analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.